The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Antibiotic‐Associated Disruption of Microbiota Composition and Function in Cirrhosis Is Restored by Fecal Transplant
Abstract
Patients with cirrhosis are often exposed to antibiotics that can lead to resistance and fungal overgrowth. The role of fecal microbial transplant (FMT) in restoring gut microbial function is unclear in cirrhosis. In a Food and Drug Administration–monitored phase 1 clinical safety trial, patients with decompensated cirrhosis on standard therapies (lactulose and rifaximin) were randomized to standard‐of‐care (SOC, no antibiotics/FMT) or 5 days of broad‐spectrum antibiotics followed by FMT from a donor enriched in Lachnospiraceae and Ruminococcaceae. Microbial composition (diversity, family‐level relative abundances), function (fecal bile acid [BA] deconjugation, 7α‐dehydroxylation, short‐chain fatty acids [SCFAs]), and correlations between Lachnospiraceae, Ruminococcaceae, and clinical variables were analyzed at baseline, postantibiotics, and 15 days post‐FMT. FMT was well tolerated. Postantibiotics, there was a reduced microbial diversity and autochthonous taxa relative abundance. This was associated with an altered fecal SCFA and BA profile. Correlation linkage changes from beneficial at baseline to negative after antibiotics. All of these parameters became statistically similar post‐FMT to baseline levels. No changes were seen in the SOC group. Conclusion: In patients with advanced cirrhosis on lactulose and rifaximin, FMT restored antibiotic‐associated disruption in microbial diversity and function. (H epatology 2018; 00:000‐000).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192
Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences
Langille, M. G. I., Zaneveld, J., Caporaso, J. G., McDonald, D., Knights, D., Reyes, J. A., Clemente, J. C., Burkepile, D. E., Vega Thurber, R. L., Knight, R., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2676 · Cited by 9,116 · cited 1×
“PiCRUST (Phylogenetic Investigation of Communities by Reconstruction of Unobserved States) analysis of the stool microbiota was also performed to define changes in predicted microbiota functionality(11).”
Vrieze, A., Van Nood, E., Holleman, F., Salojärvi, J., Kootte, R. S., Bartelsman, J. F. W. M., Dallinga–Thie, G. M., Ackermans, M. T., Serlie, M. J., Oozeer, R., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.031 · Cited by 2,913
Bile salt biotransformations by human intestinal bacteria
Ridlon, J. M., Kang, D.-J., & Hylemon, P. B. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r500013-jlr200 · Cited by 2,829
Self-citationMachiels, K., Joossens, M., Sabino, J., De Preter, V., Arijs, I., Eeckhaut, V., Ballet, V., Claes, K., Van Immerseel, F., Verbeke, K., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-304833 · Cited by 1,904 · cited 1×
“(35) SCFAs, especially butyrate, are a main energy source of the colonic epithelial cells and have overall beneficial effects to the host.(33,36-38) SCFAs also activate specific G protein– coupled receptors that regulate intestinal motility and”
BackgroundAltered profile of human gut microbiome is associated with cirrhosis and its complications
Bajaj, J. S., Heuman, D. M., Hylemon, P. B., Sanyal, A. J., White, M. B., Monteith, P., Noble, N. A., Unser, A. B., Daita, K., Fisher, A. R., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.12.019 · Cited by 1,099 · cited 5×
“The selection of the donor in this study was based on an a priori assumption that a high relative abundance of Lachnospiraceae and Ruminococcaceae would determine the most optimal outcome in the FMT recipients.(4,6) Therefore, not only was the establishment of these two taxa necessary but we also needed to study their…”
BackgroundMethodInfluentialSelf-citationLinkage of gut microbiome with cognition in hepatic encephalopathy
Bajaj, J. S., Ridlon, J. M., Hylemon, P. B., Thacker, L. R., Heuman, D. M., Smith, S., Sikaroodi, M., & Gillevet, P. M. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00190.2011 · Cited by 547 · cited 1×
“Analyses were performed using R, with published techniques to analyze differences in interactions compared to baseline and day 5 within groups as well as between groups.(12,13)”
MethodSelf-citationHospital readmissions among patients with decompensated cirrhosis
Volk, M. L., Tocco, R. S., Bazick, J., Rakoski, M. O., & Lok, A. S. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.314 · Cited by 451
Bajaj, J. S., Heuman, D. M., Sanyal, A. J., Hylemon, P. B., Sterling, R. K., Stravitz, R. T., Fuchs, M., Ridlon, J. M., Daita, K., Monteith, P., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060042 · Cited by 430 · cited 1×
“(22) Rifaximin is used extensively for HE as a second-line therapy, but its main mechanism of action could be related to bacterial function rather than simple compositional changes.(23-25) In addition, there are patients with HE who continue to recur despite the use of rifaximin, who need additional treatments and sup…”
MethodWeingarden, A. R., Chen, C., Bobr, A., Yao, D., Lu, Y., Nelson, V. M., Sadowsky, M. J., & Khoruts, A. (2014) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00282.2013 · Cited by 423
Cited by
The gut-liver axis in liver disease: Pathophysiological basis for therapy
Albillos, A., de Gottardi, A., & Rescigno, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.003 · Cited by 2,166
The gut–liver axis and gut microbiota in health and liver disease
Hsu, C. L., & Schnabl, B. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00904-3 · Cited by 737
Cammarota, G., Ianiro, G., Kelly, C. R., Mullish, B. H., Allegretti, J. R., Kassam, Z., Putignani, L., Fischer, M., Keller, J. J., Costello, S. P., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-319548 · Cited by 506
Self-citationProbiotic Gastrointestinal Transit and Colonization After Oral Administration: A Long Journey
Han, S., Lu, Y., Xie, J., Fei, Y., Zheng, G., Wang, Z., Liu, J., Lv, L., Ling, Z., Berglund, B., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.609722 · Cited by 481
EASL Clinical Practice Guidelines on the management of hepatic encephalopathy
Montagnese, S., Rautou, P.-E., Romero-Gómez, M., Larsen, F. S., Shawcross, D. L., Thabut, D., Vilstrup, H., & Weissenborn, K. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.001 · Cited by 440
Fecal microbiota transplantation in cancer management: Current status and perspectives
Chen, D., Wu, J., Jin, D., Wang, B., & Cao, H. (2019) · International Journal of Cancer · doi:10.1002/ijc.32003 · Cited by 321
Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma
Chen, C., Wang, Z., Ding, Y., & Qin, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1133308 · Cited by 305
The microbiota in cirrhosis and its role in hepatic decompensation
Trebicka, J., Macnaughtan, J., Schnabl, B., Shawcross, D. L., & Bajaj, J. S. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.013 · Cited by 268
Self-citationPromises of microbiome-based therapies
Bajaj, J. S., Ng, S. C., & Schnabl, B. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.003 · Cited by 119
Self-citationGut microbiota dysbiosis in polycystic ovary syndrome: association with obesity—a preliminary report
Liang, Y., Ming, Q., Liang, J., Zhang, Y., Zhang, H., & Shen, T. (2020) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2019-0413 · Cited by 95
Protection of Fecal Microbiota Transplantation in a Mouse Model of Multiple Sclerosis
Li, K., Wei, S., Hu, L., Yin, X., Mai, Y., Jiang, C., Peng, X., Cao, X., Huang, Z., Zhou, H., et al. (2020) · Mediators of Inflammation · doi:10.1155/2020/2058272 · Cited by 92
Kazemian, N., Ramezankhani, M., Sehgal, A., Khalid, F. M., Kalkhoran, A. H. Z., Narayan, A., Wong, G. K.-S., Kao, D., & Pakpour, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-75162-x · Cited by 61
Advances in Gut Microbiota of Viral Hepatitis Cirrhosis
Wang, Y., Pan, C. Q., & Xing, H. (2019) · BioMed Research International · doi:10.1155/2019/9726786 · Cited by 52
Metadata
- Authors
- Bajaj, J. S., Kakiyama, G., Savidge, T., Takei, H., Kassam, Z. A., Fagan, A., Gavis, E. A., Pandak, W. M., Nittono, H., Hylemon, P. B., Boonma, P., Haag, A., Heuman, D. M., Fuchs, M., John, B., Sikaroodi, M., & Gillevet, P. M.
- Venue
- Hepatology
- Published
- 2018-09-20
- Volume
- 68
- Issue
- 4
- Pages
- 1549-1558
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2801976704
- Cited by
- 144
- References
- 10
- FWCI
- 5.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.